Research for the Molecular Imaging of the HER2 Targeting Tracer

Recruiting now · Not applicable

Conditions studied: HER2 Positive or Suspicious Positive Tumors

In brief

To use the molecular PET radionuclide (Ga-68 or F-18) labelled HER2 Affibody to detect the expression of HER2 in the primary and metastatic lesions in patients with HER2 positive or suspicious positive tumors; to detect the expression heterogeneity of HER2 in the lesions and inter-lesions; to observe the change of HER2 expression in the course of treatment. To provide an approach for screening patients high expression of HER2, efficacy monitoring, drug resistance and early warning of recurrence and metastasis to achieve the individualized antitumor treatment of targeted drugs.

Key facts

Study ID

NCT04547309

Run by

Peking University Cancer Hospital & Institute

People needed

200

Starts

2020-09-07

Expected to finish

2026-08-30

Last updated by the study team

2025-03-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged > 18 years old; ECOG 0 or 1;
• Patients with HER2 positive or suspicious positive tumors;
• Has at least one measurable target lesion according to CT or MRI;
• Life expectancy ≥ 12 weeks.

You may not qualify if…

• Significant hepatic or renal dysfunction;
• Is pregnant or ready to pregnant;
• Cannot keep their states for half an hour;
• Refused to join the clinical research;
• Suffering from claustrophobia or other mental disorders;
• Any other situation that researchers considered it unsuitable to participate in the trial.

Where it is running

• Hua Zhu — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.